Tatva Chintan Pharma Chem (TATVA) — Financial Results

📢 Key Event
Q1 FY27 results show 43% YoY revenue growth to ₹1,671 crores and 86% YoY EBITDA growth to ₹323 crores, with strategic updates on semiconductor chemicals and greenfield capex.

🔄 What Changed
Revenue grew 43% YoY to ₹1,671 crores and EBITDA grew 86% YoY to ₹323 crores; planned INR200 crore greenfield facility announced; semiconductor chemicals achieved first commercial batch qualification; EBITDA margin guidance maintained at 20-22% for FY27.

🔮 What's Next
Maintaining FY27 revenue growth of 25-30% QoQ, EBITDA margins of 20-22%, and INR60 crores revenue from Electrolyte Salts (within INR40-60 crores guidance); peak revenue of INR300 crores targeted at new facility; commercialization of semiconductor chemicals post-3-4 plant trials over 2 years; hybrid battery electrolyte demand to begin commercialization in late 2026; geographic expansion under Euro 7 regulations expected beyond Europe over 3-5 years.

💡 Investor Takeaway
The company is executing on multiple high-growth initiatives including semiconductor chemicals and greenfield expansion, with margin discipline and targeted capex to drive sustainable revenue growth beyond INR850 crores capacity.

Tatva Chintan Pharma Chem reported Q1 FY27 revenue of ₹1,671 crores, up 43% YoY, and EBITDA of ₹323 crores, up 86% YoY, driven by strong growth in PTC (47% YoY) and Electrolyte Salts (76% YoY). Management highlighted progress in semiconductor chemicals, pharma intermediates, and a planned INR200 crore greenfield facility targeting peak revenue of INR300 crores. Risks include raw material volatility, though guidance for FY27 remains intact with EBITDA margins of 20-22% and revenue growth of 25-30% QoQ. The company is advancing continuous flow chemistry adoption, targeting 20-25% CAGR over 3-4 years, with major hybrid battery electrolyte demand expected to begin commercialization in late 2026. Geographic expansion under Euro 7 regulations is anticipated beyond Europe over 3-5 years, supporting long-term growth potential.

📄 View Original Announcement (PDF)

📊 Stock Analysis — TATVA ✨ Ask AI About This

About Tatva Chintan Pharma Chem Limited (TATVA)

Chemicals · Chemicals & Petrochemicals · Listed on NSE

Market Cap: ₹3,079.1 Cr P/E: 215.4

View full TATVA stock details →

📡 Get AI alerts when TATVA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track TATVA — Free

💡 Ask AI about this filing

"What is the expected revenue contribution from the semiconductor chemicals segment by FY28?" "How will the INR200 crore greenfield facility impact peak revenue capacity and margins?" "When will hybrid battery electrolyte demand achieve full commercialization and revenue scale?"

Ask AI Free →

📊 More TATVA filings

See all TATVA filings →

🔥 Also filed on 21 July 2026

AARTIIND Aarti Industries Limited Financial Results ANTHEM Anthem Biosciences Limited Financial Results MUFIN Mufin Green Finance Limited Corporate Action ABCAPITAL Aditya Birla Capital Limited Announcement CYIENTDLM Cyient DLM Limited Financial Results KIOCL KIOCL Limited Insider Trading

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when TATVA files new disclosures

Track TATVA filings, board meetings, and corporate actions. Free email alerts at 5 PM.